Early Breast Cancer Trialists’ Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84.

Article  Google Scholar 

Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–717.

Article  Google Scholar 

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–220.

Article  CAS  PubMed  Google Scholar 

Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol. 2019;37(5):423–38.

Article  CAS  PubMed  Google Scholar 

Gnant M, Fitzal F, Rinnerthaler G, Steger GG, Greil-Ressler S, Balic M, et al. Duration of adjuvant aromatase-inhibitor therapy in postmenopausal breast cancer. N Engl J Med. 2021;385(5):395–405.

Article  CAS  PubMed  Google Scholar 

Jordan VC. 50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened? Endocr Relat Cancer. 2021;28(1):R11–30.

Article  MathSciNet  PubMed  PubMed Central  Google Scholar 

Martinkovich S, Shah D, Planey SL, Arnott JA. Selective estrogen receptor modulators: tissue specificity and clinical utility. Clin Interv Aging. 2014;9:1437–52.

PubMed  PubMed Central  Google Scholar 

Stearns V, Ullmer L, López JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet. 2002;360(9348):1851–61.

Article  CAS  PubMed  Google Scholar 

Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention. The NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2742–51.

Article  CAS  PubMed  Google Scholar 

Swerdlow AJ, Jones ME, British Tamoxifen Second Cancer Study G. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst. 2005;97(5):375–84.

Article  CAS  PubMed  Google Scholar 

Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361(9354):296–300.

Article  CAS  PubMed  Google Scholar 

Buijs SM, van Dorst DCH, Kruip MJHA, van den Akker RFP, Cheung KL, Porrazzo R, et al. The interplay between tamoxifen and endoxifen plasma concentrations and coagulation parameters in patients with primary breast cancer. Biomed Pharmacother. 2024;170: 115969.

Article  CAS  PubMed  Google Scholar 

Boehm DU, Lebrecht A, Eckhardt T, Albrich S, Schmidt M, Siggelkow W, et al. Quality of life and adjuvant tamoxifen treatment in breast cancer patients. Eur J Cancer Care. 2009;18(5):500–6.

Article  Google Scholar 

Owusu C, Buist DSM, Field TS, Lash TL, Thwin SS, Geiger AM, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol. 2008;26(4):549–55.

Article  PubMed  Google Scholar 

Lailler G, Memoli V, Le Bihan BC, Ben Diane M-K, Lauzier S, Mancini J, et al. Five-year adjuvant endocrine therapy adherence trajectories among women with breast cancer: a nationwide french study using administrative data. Clin Breast Cancer. 2021;21(4):e415–26.

Article  CAS  PubMed  Google Scholar 

Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134(2):459–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bosco-Lévy P, Jové J, Robinson P, Moore N, Fourrier-Réglat A, Bezin J. Persistence to 5-year hormonal breast cancer therapy: a French national population-based study. Br J Cancer. 2016;115(8):912–9.

Article  PubMed  PubMed Central  Google Scholar 

Mulder TAM, de With M, Del Re M, Danesi R, Mathijssen RHJ, van Schaik RHN. Clinical CYP2D6 genotyping to personalize adjuvant tamoxifen treatment in ER-positive breast cancer patients: current status of a controversy. Cancers (Basel). 2021;13(4):771.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95(23):1758–64.

Article  CAS  PubMed  Google Scholar 

Coezy E, Borgna JL, Rochefort H. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 1982;42(1):317–23.

CAS  Google Scholar 

Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89(5):708–17.

Article  PubMed  Google Scholar 

Helland T, Henne N, Bifulco E, Naume B, Borgen E, Kristensen VN, et al. Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients. Breast Cancer Res. 2017;19(1):125.

Article  PubMed  PubMed Central  Google Scholar 

Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89(5):718–25.

Article  CAS  PubMed  Google Scholar 

Saladores P, Mürdter T, Eccles D, Chowbay B, Zgheib NK, Winter S, et al. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer. Pharmacogenomics J. 2015;15(1):84–94.

Article  CAS  PubMed  Google Scholar 

Groenland SL, van Eerden RAG, Westerdijk K, Meertens M, Koolen SLW, Moes D, et al. Therapeutic drug monitoring based precision dosing of oral targeted therapies in oncology: a prospective multicentre study. Ann Oncol. 2022;33(10):1071–82.

Article  CAS  PubMed  Google Scholar 

Groenland SL, Verheijen RB, Joerger M, Mathijssen RHJ, Sparreboom A, Beijnen JH, et al. Precision dosing of targeted therapies is ready for prime time. Clin Cancer Res. 2021;27(24):6644–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neven P, Jongen L, Lintermans A, Van Asten K, Blomme C, Lambrechts D, et al. Tamoxifen metabolism and efficacy in breast cancer: a prospective multicenter trial. Clin Cancer Res. 2018;24(10):2312–8.

Article  CAS  PubMed  Google Scholar 

Sanchez-Spitman A, Dezentjé V, Swen J, Moes DJAR, Böhringer S, Batman E, et al. Tamoxifen pharmacogenetics and metabolism: results from the prospective CYPTAM study. J Clin Oncol. 2019;37(8):636–46.

Article  CAS  PubMed  Google Scholar 

Braal CL, Beijnen JH, Koolen SLW, Oomen-de Hoop E, Steeghs N, Jager A, et al. Relevance of endoxifen concentrations: absence of evidence is not evidence of absence. J Clin Oncol. 2019;37(22):1980–1.

Article  CAS  PubMed  Google Scholar 

Jager NG, Koornstra RH, Vincent AD, van Schaik RH, Huitema AD, Korse TM, et al. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. BMC Cancer. 2013;13:612.

Article  PubMed  PubMed Central  Google Scholar 

Peyrade F, Frenay M, Etienne MC, Ruch F, Guillemare C, François E, et al. Age-related difference in tamoxifen disposition. Clin Pharmacol Ther. 1996;59(4):401–10.

Article  CAS  PubMed  Google Scholar 

Gallicchio L, Lord G, Tkaczuk K, Danton M, Lewis LM, Lim CK, et al. Association of Tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer. Breast Cancer Res Treat. 2004;85(1):89–97.

Article  CAS  PubMed  Google Scholar 

Lorizio W, Wu AHB, Beattie MS, Rugo H, Tchu S, Kerlikowske K, et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012;132(3):1107–18.

Article  CAS  PubMed  Google Scholar 

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2018;16(3):310–20.

Article  Google Scholar 

Visvanathan K, Fabian CJ, Bantug E, Brewster AM, Davidson NE, DeCensi A, et al. Use of endocrine therapy for breast cancer risk reduction: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(33):3152–65.

Article  CAS  PubMed  Google Scholar 

Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24. J Clin Oncol. 2012;30(12):1268–73.

Article  CAS  PubMed  PubMed Central